CareDx (CDNA) investor relations material

Strategic opportunities and market outlook

• Early-stage adoption of molecular monitoring in organ transplantation presents significant growth potential, with increasing standard-of-care acceptance and a long runway for expansion.

• The company is recognized as an innovator, with a 25-year mission focused on improving patient outcomes through advanced diagnostics and patient-centered solutions.

• Solutions-based selling, including software, IVD kits, and molecular monitoring, has driven strong adoption, especially in kidney transplant surveillance.

• Over 60 transplant centers have adopted surveillance protocols, with more than 200 potential programs in the U.S., indicating substantial room for further penetration.

• Clinical data and published studies are accelerating adoption, with surveillance testing enabling earlier detection and intervention for organ rejection.

Operational execution and technology integration

• Implementation of Epic EHR integration is expected to streamline administrative processes and support protocol adherence, targeting 10% of volume by year-end and aiming for 50% by the end of next year.

• Administrative and IT complexities at hospital systems are the main gating factors for broader Epic adoption, but recent perfect implementation scores signal strong execution.

• Investments in digital solutions, including SaaS transitions and cloud upgrades, are enhancing efficiency and value for transplant centers.

Financial performance and revenue management

• Revenue cycle management overhaul has improved workflows, automation, and team expertise, targeting a 7% ASP increase to $1,400 by the first half of 2025.

• Cleaning up legacy claims resulted in a $5 million write-off, but future periods are expected to be free of such negative impacts.

• Strong balance sheet with no debt and nearly $200 million in cash supports ongoing investments in growth, including a 50% expansion of the sales force.